BPC-157 vs TB-500: Key Differences for Research
Published: 2026-03-07Updated: 2026-03-10Category: Comparisons
BPC-157 and TB-500 are the two most studied cytoprotective peptides in preclinical literature. Both are frequently referenced together — sometimes called the "Wolverine Stack" — but they operate through different mechanisms and have different research profiles. This guide breaks down the published science on each.
Structural Overview
| Property | BPC-157 | TB-500 |
|---|
| Full Name | Body Protection Compound-157 | Thymosin Beta-4 Fragment |
| Amino Acids | 15 | 43 (active fragment) |
| Origin | Derived from human gastric juice protein | Derived from Thymosin Beta-4 |
| CAS Number | 137525-51-0 | 77591-33-4 |
| Primary Research Area | Cytoprotective / GI biology | Cell migration / tissue remodeling |
| Published Studies | 100+ preclinical | 50+ preclinical |
| FDA Status | Category 2 (not approved) | Category 2 (not approved) |
Mechanism of Action (Published Research)
BPC-157
In preclinical studies, BPC-157 has been observed to upregulate growth factor receptors (VEGF, FGF), modulate the nitric oxide (NO) system, and influence the FAK-paxillin signaling pathway. It is one of the few peptides studied extensively in GI tract models — its gastroprotective properties were the original research focus. Published animal studies have reported observations in tendon, ligament, muscle, and bone tissue models.
TB-500
TB-500 (the active fragment of Thymosin Beta-4) has been studied primarily for its role in actin polymerization and cell migration. In preclinical models, it has been observed to influence blood vessel formation and modulate NF-kB inflammatory signaling pathways. Research has focused on cardiac, dermal, and corneal tissue models.
Key Published Studies
| Study Focus | BPC-157 | TB-500 |
|---|
| Tendon biology | Observed accelerated tendon-to-bone remodeling in rat models (Chang et al., 2011) | Limited tendon-specific data; studied primarily in cardiac models |
| GI tract | Extensive — gastroprotective in multiple ulcer models, observed mucosal effects | Not a primary research focus |
| Cardiac models | Observed post-MI cardiac tissue remodeling (Sikirić et al., 2018) | Observed myocardial remodeling and vascular biology effects (Hinkel et al., 2015) |
| Inflammatory markers | Observed TNF-alpha and IL-1beta modulation in animal models | Observed NF-kB pathway modulation |
How They Differ
The key distinction in published literature is specificity of research context. BPC-157 has the broader preclinical research base, with studies spanning GI, musculoskeletal, CNS, and vascular models. TB-500 research is more concentrated in cell migration, cardiac biology, and wound models. BPC-157 is unique in its observed gastric effects — no other peptide in the research category has comparable published GI data.
Research context: Many published protocols reference both peptides together, but they act through different pathways. BPC-157 is primarily studied for its cytoprotective and NO-mediated effects, while TB-500 is studied for actin-dependent cell migration and vascular biology. Both are available at Pepta Labs:
BPC-157 |
TB-500
Availability
Both BPC-157 and TB-500 were placed on the FDA's Category 2 list in September 2023, prohibiting their use in compounding pharmacies. They remain available as research chemical reference materials from suppliers like Pepta Labs, labeled for in-vitro laboratory use only.
All information is sourced from published peer-reviewed literature and provided for educational purposes only. This content does not represent claims about products sold by Pepta Labs. All products are chemical reference materials for in-vitro laboratory research only. Not for human or animal consumption. See
Terms of Service and
Compliance Policy.
Browse Research Compounds
34+ peptides. Third-party COAs. Free US shipping.
View Catalog →